ArticleEye (London, England)2026
Transition from intermediate to late AMD and associated changes in vision by two years in a multicentre cohort study in Europe- INTERCEPT-AMD Report 3.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesThe aim was to evaluate the incidence of late AMD in eyes with intermediate AMD (iAMD) over two years. SUBJECTS/
methodsIn this multicentre cohort study, participants with iAMD were classified as: (i) iAMD without incomplete retinal pigment epithelium or outer retinal atrophy (iRORA) or subretinal drusenoid deposits (SDD); (ii) iAMD with SDD with no iRORA; (iii) iAMD with iRORA with no SDD and (iv) iAMD with iRORA and SDD. Factors associated with the incidence of late AMD were analysed using an interval-censored Weibull parametric proportional hazards model.
results983 eyes from 805 participants were analysed. Model-based cumulative incidence at nominal 2 years was 13.1% (95% CI 10.8-15.6%) for late AMD, 7.6% (95% CI 5.9-9.3%) for nAMD as the cause and 5.5% (95% CI 4.1-7.3%) for cRORA as the cause. Participants aged 75-84 (adjusted HR [aHR] 1.66, 95% CI 1.13-2.46; P = 0.01), 85 years+ (aHR 2.48, 95% CI 1.49-4.15; P = 0.001), presence of iRORA (aHR 1.50, 95% CI 1.05-2.16; P = 0.03), fellow-eye nAMD (aHR 3.23, 95% CI 2.04-5.12; P < 0.001) and BRVA 70-79 (vs 80 or better ETDRS letters: aHR 1.65, 95% CI 1.09-2.49; P = 0.02) had increased hazard of late AMD. Eyes that transitioned to neovascular AMD (nAMD) by 2 years (within tolerance window) displayed the greatest loss in BRVA compared to other phenotypes (-6.01 letters, SD 11.35).
conclusionsApproximately 13% of eyes with iAMD progressed to late AMD within 2 years. Eyes that transitioned to nAMD experienced the greatest loss in BRVA.
Identifiers
42595769What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.